Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00382200 · ClinicalTrials.gov registry record · Phase 1
Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT00382200: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00382200 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00382200, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of myelodysplastic cells, either by killing the cells or by stopping them from dividing. Tretinoin and decitabine may help myelodysplastic cells become more like normal cells, and to grow and spread more slowly. Giving decitabine together with tretinoin may be an effective treatment for myelodysplastic syndromes. PURPOSE: This phase I/II trial is studying the side effects and best dose of tretinoin when given together with decitabine in treating patients with myelodysplastic syndromes.
Interventions
- GENETIC microarray analysis
- DRUG decitabine
- GENETIC DNA methylation analysis
- GENETIC cytogenetic analysis
- DRUG tretinoin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2006-07 |
| Est. Completion | 2023-01-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00382200
The ClinicalTrials.gov registry entry for NCT00382200 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which microarray analysis is the first listed.
NCT00382200 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00382200 about?
NCT00382200 is a clinical study titled "Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes". RATIONALE: Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of myelodysplastic cells, either by killing the cells or by stopping them from dividing. Tretinoin and decitabine may help myelodysplastic cells become more like normal cells, and to grow and spread ...
What is the current status of trial NCT00382200?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2006-07. Estimated completion is 2023-01-05.
What interventions are being tested in trial NCT00382200?
The interventions under investigation include: microarray analysis (GENETIC), decitabine (DRUG), DNA methylation analysis (GENETIC), cytogenetic analysis (GENETIC), tretinoin (DRUG).
Who is sponsoring clinical trial NCT00382200?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.